Huisheng Biopharmaceuticals Co.,Ltd.is a comprehensive pharmaceutical enterprise established by the Sihuan Pharmaceutical Holding Group in accordance with its strategic development plan.It focuses on the treatment of diabetes and metabolic diseases,covering both biological products and small molecular drugs with a complete product pipeline.
The pipeline of products that are under R&D includes innovative drugs such as Ganagliflozin Proline Tablets,a full range of insulins,GLP-1 analogues,and 30+medications for diabetes and its complications with different mechanisms,which covers the entire treatment and scope in the field of diabetes and complications.Among them,Ganagliflozin Proline Tablets is the only drug of the first category to be approved in Jilin Province in the past five years.It has obtained 28 patent authorizations in 6 countries and regions including China,the United States,Japan,Europe,etc.After nearly a decade of development,Huisheng's products were approved one after another by the end of 2023.Up to now,we have obtained 20 product marketing approval certificates,including the national first-class innovative drug Ganagliflozin Proline Tablets,the first biosimilar product of insulin degludec series,and other small molecular drugs.
Huisheng Biopharm has a state-of-the-art drug production base with advanced technology and first-class equipment.It not only complies with domestic GMP standards,but also meets FDA and EU standards.The biopharmaceutical base is equipped with various-scale fermentation,purification and other equipment from small-scale trials to industrialization.After the second-phase expansion,the production capacity will exceed 100 million doses.At the same time,Huisheng has a team of biopharmaceutical innovation drug,a team of biosimilar drug and clinical research team with 4 major innovative technology platforms.It also has a research and development team of over 150 people,covering the entire process from early research to later clinical development.Huisheng Biopharm will gradually establish a direct selling mode+distribution mode,offline+online marketing models,covering 34 provinces across the country,radiating to 4 major regions and having over 10,000 distributors and their sales teams.